Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study.
chronic lymphocytic leukemia
circulating miRNA
prospective study
serum
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 09 2020
01 09 2020
Historique:
received:
29
08
2019
revised:
18
11
2019
accepted:
17
12
2019
pubmed:
6
2
2020
medline:
7
4
2021
entrez:
4
2
2020
Statut:
ppublish
Résumé
Chronic lymphocytic leukemia (CLL) is an incurable disease accounting for almost one-third of leukemias in the Western world. Aberrant expression of microRNAs (miRNAs) is a well-established characteristic of CLL, and the robust nature of miRNAs makes them eminently suitable liquid biopsy biomarkers. Using a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC), the predictive values of five promising human miRNAs (hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p), identified in a pilot study, were examined in serum of 224 CLL cases (diagnosed 3 months to 18 years after enrollment) and 224 matched controls using Taqman based assays. Conditional logistic regressions were applied to adjust for potential confounders. The median time from blood collection to CLL diagnosis was 10 years (p25-p75: 7-13 years). Overall, the upregulation of hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-29a-3p was associated with subsequent risk of CLL [OR
Substances chimiques
Biomarkers, Tumor
0
MicroRNAs
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1315-1324Subventions
Organisme : Worldwide Cancer Research
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC-PC_13048
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC-UU_12015/1 (to EPIC-Norfolk study DOI 10.22025/
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N003284/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8221/A19170
Pays : United Kingdom
Organisme : Medical Research Council
ID : G1000143
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M012190/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0401527
Pays : United Kingdom
Organisme : Cancer Research UK
ID : 14136
Pays : United Kingdom
Informations de copyright
© 2020 UICC.
Références
Sant M, Minicozzi P, Mounier M, et al. Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study. Lancet Oncol 2014;15:931-42.
Chiorazzi N, Dameshek W, Rai KR, et al. Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. Best Pract Res Clin Haematol 2007;20:399-413.
Rawstron AC, Bennett FL, O'Connor JMS, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med 2008;359:575-83.
Nieto WG, Almeida J, Romero A, et al. Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. Blood 2009;114:33-7.
Lawrie CH. MicroRNAs and haematology: small molecules, big function. Br J Haematol 2007;137:503-12.
Storz G. An expanding universe of noncoding RNAs. Science (80- ) 2002;296:1260-3.
Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-9.
Pekarsky Y, Balatti V, Croce CM. BCL2 and miR-15/16: from gene discovery to treatment. Cell Death Differ 2018;25:21-6.
Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008;141:672-5.
Lawrie CH. MicroRNAs in hematological malignancies. Blood Rev 2013;27:143-54.
Larrea E, Sole C, Manterola L, et al. New concepts in Cancer biomarkers: circulating miRNAs in liquid biopsies. Int J Mol Sci 2016;17:627.
Solé C, Arnaiz E, Lawrie CH. MicroRNAs as biomarkers of B-cell lymphoma. Biomark Insights 2018;13:1177271918806840.
van Roosbroeck K, Calin GA, Author SO. MicroRNAs in CLL: miRacle or miRage for prognosis and targeted therapies? HHS public access Author manuscript. Semin Oncol 2016;43:209-14.
Yeh Y-Y, Ozer HG, Lehman AM, et al. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. Blood 2015;125:3297-305.
Calin GA, Ferracin M, Cimmino A, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353:1793-801.
Riboli E, Kaaks R. The EPIC project: rationale and study design. European prospective investigation into Cancer and nutrition. Int J Epidemiol 1997;26(Suppl 1):S6-14.
Riboli E, Hunt KJ, Slimani N, et al. European prospective investigation into Cancer and nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113-24.
de Sanjose S, Shah KV, Domingo-Domenech E, et al. Lack of serological evidence for an association between simian virus 40 and lymphoma. Int J Cancer 2003;104:522-4.
He Y, Jiang X, Chen J. The role of miR-150 in normal and malignant hematopoiesis. Oncogene 2014;33:3887-93.
Due H, Svendsen P, Bødker JS, et al. miR-155 as a biomarker in B-cell malignancies. Biomed Res Int 2016;2016:1-14.
Vigorito E, Kohlhaas S, Lu D, et al. miR-155: an ancient regulator of the immune system. Immunol Rev 2013;253:146-57.
Mraz M, Chen L, Rassenti LZ, et al. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood 2014;124:84-95.
Fulci V, Chiaretti S, Goldoni M, et al. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 2007;109:4944-51.
Filip AA, Grenda A, Popek S, et al. Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle. Ann Hematol 2016;96:33-50.
Cui B, Chen L, Zhang S, et al. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. Blood 2014;124:546-54.
Stamatopoulos B, Van Damme M, Crompot E, et al. Opposite prognostic significance of cellular and serum circulating microRNA-150 in chronic lymphocytic leukemia patients. Mol Med 2015;21:123-33.
Moussay E, Wang K, Cho J-H, et al. MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2011;108:6573-8.
Kaaks R, Sookthai D, Luczynska A, et al. Lag times between lymphoproliferative disorder and clinical diagnosis of chronic lymphocytic leukemia: a prospective analysis using plasma soluble CD23. Cancer Epidemiol Biomarkers Prev 2015;24:538-45.
Landgren O, Albitar M, Abbasi F, et al. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med 2009;360:659-67.
Vardi A, Dagklis A, Scarfo L, et al. Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood 2013;121:4521-8.
Ferrajoli A, Shanafelt TD, Ivan C, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood 2013;122:1891-9.
Orfao A, Criado I, Rodríguez-Caballero A, et al. Low-count monoclonal B-cell lymphocytosis persists after 7 years of follow-up and confers a higher risk of death. Blood 2017;130:4299.
Shanafelt T, Kay N, Hanson C, et al. Prevalence of low count (LC) monoclonal B cell lymphocytosis (MBL) and serious infections in a population-based cohort of U.S. adults participating in a large bio-repository. Blood 2017;130:831.
Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013;121:1612-21.
Anderson LA, Landgren O, Engels EA. Common community acquired infections and subsequent risk of chronic lymphocytic leukaemia. Br J Haematol 2009;147:444-9.
Landgren O, Rapkin JS, Caporaso NE, et al. Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood 2007;109:2198-201.
Beldomenico PM, Begon M. Disease spread, susceptibility and infection intensity: vicious circles? Trends Ecol Evol 2010;25:21-7.
Gracias DT, Stelekati E, Hope JL, et al. The microRNA miR-155 controls CD8(+) T cell responses by regulating interferon signaling. Nat Immunol 2013;14:593-602.
Tsai C-Y, Allie SR, Zhang W, et al. MicroRNA miR-155 affects antiviral effector and effector memory CD8 T cell differentiation. J Virol 2013;87:2348-51.
Lind EF, Elford AR, Ohashi PS. Micro-RNA 155 is required for optimal CD8+ T cell responses to acute viral and intracellular bacterial challenges. J Immunol 2013;190:1210-6.
Chen Z, Stelekati E, Kurachi M, et al. miR-150 regulates memory CD8 T cell differentiation via c-Myb. Cell Rep 2017;20:2584-97.
Ban YH, Oh S-C, Seo S-H, et al. miR-150-mediated Foxo1 regulation programs CD8 + T cell differentiation. Cell Rep 2017;20:2598-611.
Schmitt MJ, Margue C, Behrmann I, et al. MiRNA-29: a microRNA family with tumor-suppressing and immune-modulating properties. Curr Mol Med 2013;13:572-85.
Virgilio L, Narducci MG, Isobe M, et al. Identification of the TCL1 gene involved in T-cell malignancies. Proc Natl Acad Sci USA 1994;91:12530-4.
Pekarsky Y, Santanam U, Cimmino A, et al. Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 2006;66:11590-3.
Stamatopoulos B, Meuleman N, Haibe-Kains B, et al. microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 2009;113:5237-45.
Ferrer G, Navarro A, Hodgson K, et al. MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemia. Leuk Lymphoma 2013;54:2016-22.
Mertens D, Stilgenbauer S. CLL and deletion 13q14: merely the miRs? Blood 2012;119:2974-5.
Isaksson A, Wallman M, Göransson H, et al. Cross-validation and bootstrapping are unreliable in small sample classification. Pattern Recognit Lett 2008;29:1960-5.